4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from HC Wainwright

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $36.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 307.70% from the company’s current price.

FDMT has been the subject of several other research reports. Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday. Leerink Partners reiterated an “outperform” rating and set a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Chardan Capital raised their price objective on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Finally, BMO Capital Markets lowered their target price on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, July 18th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

4D Molecular Therapeutics Trading Up 10.1 %

Shares of NASDAQ FDMT opened at $8.83 on Thursday. The stock has a fifty day simple moving average of $10.30 and a two-hundred day simple moving average of $17.13. 4D Molecular Therapeutics has a 1-year low of $7.32 and a 1-year high of $36.25. The firm has a market cap of $458.90 million, a price-to-earnings ratio of -3.10 and a beta of 2.82.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth $40,000. Values First Advisors Inc. purchased a new position in 4D Molecular Therapeutics during the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. increased its stake in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after acquiring an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $108,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after acquiring an additional 3,026 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.